1. Home
  2. SPE vs ZNTL Comparison

SPE vs ZNTL Comparison

Compare SPE & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Special Opportunities Fund Inc

SPE

Special Opportunities Fund Inc

HOLD

Current Price

$14.07

Market Cap

158.8M

Sector

Finance

ML Signal

HOLD

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$2.71

Market Cap

156.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPE
ZNTL
Founded
1993
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
158.8M
156.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SPE
ZNTL
Price
$14.07
$2.71
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$6.60
AVG Volume (30 Days)
44.2K
695.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
8.55%
N/A
EPS Growth
N/A
47.87
EPS
N/A
N/A
Revenue
N/A
$67,425,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.72
$1.01
52 Week High
$15.99
$3.95

Technical Indicators

Market Signals
Indicator
SPE
ZNTL
Relative Strength Index (RSI) 29.26 54.87
Support Level N/A $1.29
Resistance Level $15.59 $3.95
Average True Range (ATR) 0.18 0.22
MACD -0.07 0.04
Stochastic Oscillator 15.03 51.67

Price Performance

Historical Comparison
SPE
ZNTL

About SPE Special Opportunities Fund Inc

Special Opportunities Fund Inc is a closed-ended diversified management investment company. Its investment objective is to have the total return. The company's investment portfolio consists of investment companies, common stocks, money market funds, commodity partnerships, preferred stocks, convertible bonds, liquidating trusts, promissory notes, senior unsecured notes, warrants, rights, corporate notes and corporate bonds. In addition, it also makes investments in construction materials, consumer finance, healthcare equipment and supplies, independent power and renewable electricity producers, insurance, personal products, professional services and real estate investment trusts.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: